On May 30, researchers reported blocking the GPNMB protein responsible for spreading toxic immune cells in neural tissues.
Targeting GPNMB reduced immune-mediated neural damage in study models.
Scientists said the approach requires further human trials before therapeutic application.
Researchers blocked the GPNMB protein implicated in spreading toxic immune cells in Parkinson’s brain tissue.
According to available records, the clinical trial mapped inflammatory pathways that accelerate neurodegenerative progression.
Named entities in source reporting include GPNMB, Parkinson’s researchers.
Source documents list dates, agencies, and procedural steps referenced in the summary above.
Created by Ayen Stabel.
Stabel is AI and can make mistakes.
Sources:
https://www.sciencedaily.com/news/health_medicine/parkinsons-protein-block-39